Go offline with the Player FM app!
Are mitochondrial therapeutics about to go mainstream?
Manage episode 472586786 series 3361449
Mitochondria are famously the powerhouse of the cell, but will mitochondrial therapeutics power the next big mainstream medical breakthrough?
Klaus Dugi is CEO of Vandria, a biotech that develops mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. He joins 'Beyond Biotech' to talk cell mitophagy, biotech agility, and innovation in tackling neurodegenerative disease.
00:42 Introducing Klaus Dugi
02:51 Lessons learned in top pharma
05:10 The gap that Vandria seeks to fill
06:21 Mitochondrial therapeutics
07:45 Mitophagy inducers and how they work
14:53 Comparing approaches to treating neurodegenerative diseases
17:20 Aging, longevity, and healthy life years
25:26 Challenges ahead
27:31 Performance enhancement and resilience
31:15 Towards the mainstream?
34:35 Looking forward for Vandria
36:02 Developments to watch out for in mitochondrial therapeutics
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
Chapters
1. Are mitochondrial therapeutics about to go mainstream? (00:00:00)
2. Introducing Klaus Dugi (00:00:42)
3. Lessons learned in top pharma (00:02:51)
4. The gap that Vandria seeks to fill (00:05:10)
5. Mitochondrial therapeutics (00:06:21)
6. Mitophagy inducers and how they work (00:07:45)
7. Comparing approaches to treating neurodegenerative diseases (00:14:53)
8. Aging, longevity, and healthy life years (00:17:20)
9. Challenges ahead (00:25:26)
10. Performance enhancement and resilience (00:27:31)
11. Towards the mainstream? (00:31:15)
12. Looking forward for Vandria (00:34:35)
13. Developments to watch out for in mitochondrial therapeutics (00:36:02)
146 episodes
Manage episode 472586786 series 3361449
Mitochondria are famously the powerhouse of the cell, but will mitochondrial therapeutics power the next big mainstream medical breakthrough?
Klaus Dugi is CEO of Vandria, a biotech that develops mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. He joins 'Beyond Biotech' to talk cell mitophagy, biotech agility, and innovation in tackling neurodegenerative disease.
00:42 Introducing Klaus Dugi
02:51 Lessons learned in top pharma
05:10 The gap that Vandria seeks to fill
06:21 Mitochondrial therapeutics
07:45 Mitophagy inducers and how they work
14:53 Comparing approaches to treating neurodegenerative diseases
17:20 Aging, longevity, and healthy life years
25:26 Challenges ahead
27:31 Performance enhancement and resilience
31:15 Towards the mainstream?
34:35 Looking forward for Vandria
36:02 Developments to watch out for in mitochondrial therapeutics
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
Chapters
1. Are mitochondrial therapeutics about to go mainstream? (00:00:00)
2. Introducing Klaus Dugi (00:00:42)
3. Lessons learned in top pharma (00:02:51)
4. The gap that Vandria seeks to fill (00:05:10)
5. Mitochondrial therapeutics (00:06:21)
6. Mitophagy inducers and how they work (00:07:45)
7. Comparing approaches to treating neurodegenerative diseases (00:14:53)
8. Aging, longevity, and healthy life years (00:17:20)
9. Challenges ahead (00:25:26)
10. Performance enhancement and resilience (00:27:31)
11. Towards the mainstream? (00:31:15)
12. Looking forward for Vandria (00:34:35)
13. Developments to watch out for in mitochondrial therapeutics (00:36:02)
146 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.